Restoring, releasing or replacing adaptive immunity in chronic hepatitis B

Area of Science:

• Immunology
• Hepatology
• Virology

Background:

• Hepatitis B virus (HBV) infection is a persistent global health challenge, causing significant mortality.
• Current therapeutic strategies aim for sustained, off-treatment suppression of HBV.
• Restoring HBV-specific adaptive immunity is crucial for long-term control of residual infection.

Purpose of the Study:

• To elucidate key components of effective T cell and B cell responses against HBV.
• To explore the interactions between T cell and B cell immunity in the context of HBV.
• To review emerging immunotherapies for restoring or replacing endogenous adaptive immunity.

Main Methods:

• Review and synthesis of current research on HBV immunology and immunotherapy.
• Analysis of T cell and B cell specificities, effector functions, and intrahepatic immunity.
• Evaluation of direct and indirect immunotherapeutic approaches and their limitations.

Main Results:

• Successful control of HBV relies on robust, specific T cell and B cell responses.
• Intrahepatic immunity and the balance between protective and pathogenic immune responses are critical.
• Various immunotherapies show potential for restoring or replacing adaptive immunity against HBV.

Conclusions:

• Understanding T cell and B cell interactions is key to developing effective HBV immunotherapies.
• Emerging therapies aim to harness or supplement the host immune system for HBV suppression.
• Targeted cell or antibody infusions represent an alternative strategy for treating HBV.